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OBJECTIVES: To analyse the cost-effectiveness of adding adju-
vant postoperative radiotherapy (RT) to medical therapy after
breast conservation surgery in Stages I–II breast cancer in
Sweden. METHODS: A stochastic decision analytic model
follows patients from primary breast conservation therapy
during adjuvant therapy and includes ﬁve possible events of local
or regional events, metastases and death. Clinical data were
taken from a randomised clinical trial (SweBCG 91-RT) includ-
ing 1187 women aged 75 or younger who had received breast
conservation surgery and axillary dissection in Sweden between
1991 and 1997 and with a median follow-up of ﬁve years. Data
on health care costs were taken from a breast cancer register, a
health care database including all hospital and primary care con-
tacts in the West Health care Region. Costs for pharmaceuticals,
hospice, homecare and values of utilities were taken from the lit-
erature. RESULTS: Model results show a ten years risk of local
and regional event of 24.1 and 8.4 percent for the no RT and
RT groups, respectively. There was a signiﬁcant increase in
average Quality Adjusted Life Years (QALYs) of 0.13 (from 7.60
to 7.73) but no signiﬁcant difference in average life expectancy.
Treatment costs increased from SEK97,467 (€10,800) to
SEK101,453 (€11,300) per patient. RT shows an incremental
cost per QALY of SEK 32,000 (€3600). Model applications for
15 and 20 years results in cost savings due to a larger amount
of prevented relapses. Considering RT as an add-on to novel
adjuvant medical treatments regimens will however, reduce the
incremental beneﬁt of radiotherapy and the subsequent cost
offsets. CONCLUSIONS: Postoperative RT is cost-effective for
pre- and postmenopausal breast cancer women with Stage I–II
undergoing breast conservation therapy in Sweden only as an
adjunction to no medical adjuvant treatment. As an adjunct to
novel adjuvant medical therapies, RT is cost-effective in high-
risk groups.
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OBJECTIVES: In 2005, bortezomib received regulatory
approval in Canada for the treatment of multiple myeloma
(MM) patients who have relapsed following front-line therapy
and are refractory to their most recent therapy. Prior to this
approval, treatment options for this patient group were very
limited and included best supportive care (BSC). The objective
was to conduct an economic analysis of bortezomib versus BSC
in relapsed and refractory MM patients. METHODS: The clin-
ical evidence (survival and QOL) for the analysis was taken from
the SUMMIT trial (NEJM 2003;384:2609–2617), a Phase II trial
of bortezomib in 202 relapsed and refractory MM patients.
These patients were heavily pre-treated with a median of six
prior lines of therapy. In order to properly represent such a
refractory group of patients, the Progressive Disease subgroup of
patients in SUMMIT were used to estimate how a BSC group
would perform. Utility score was indirectly obtained from
mapping patient QOL (EORTC-QLQC30, MY24, FACIT-
Fatigue, FACT/GOG-Ntx) onto dimensions in ED-5D. Resource
use from SUMMIT was used to estimate costs from the Ontario
Ministry of Health perspective. RESULTS: Bortezomib produced
a survival gain of 9.95 months (range 7.75 to 12.09 months), 
a QALY gain of 0.53 QALY, and an incremental cost of
CAN$37,662 per patient. The incremental cost-effectiveness
ratio (ICER) was CAN$45,399 (range $37,380 to $58,288) per
LY and incremental cost-utility ratio (ICUR) was CAN$70,852
(range $58,189 to $89,791) per QALY. Sensitivity analyses did
not produce wide changes in the ICER or ICUR. CONCLU-
SIONS: Bortezomib is a cost-effective option for this patient pop-
ulation that has limited available therapies.
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OBJECTIVES: A drug protocol that incorporated docetaxel with
the conventional anticancer agents doxorubicin and cyclophos-
phamide (TAC) has shown better efﬁcacy than 5-FU with the
same agents (FAC) in terms of disease-free survival and overall
survival, in a long term (5 year) randomised controlled trial in
women with early breast cancer (BCIRG001 trial). Considering
the cost difference between the two regimens and the potentially
large number of patients affected by this new indication, an eco-
nomic assessment was deemed necessary. METHODS: In order
to assess long term costs and effectiveness of both regimens
beyond the time scope of the trial, we developed a lifetime
Markov model comparing TAC and FAC. Four health states
were deﬁned: alive without relapse, alive with loco-regional
relapse, alive with distant relapse and dead. Transitions occurred
every 6 months accordingly to time dependent transition proba-
bilities derived from the clinical trial. Model consistency was
checked against the 5-year trial results. We took into account
costs of initial chemotherapy, of severe (grade 3/4) adverse events
(febrile neutropenia, stomatitis, diarrhoea, infection), of sec-
ondary prophylaxis with growth factors and of follow-up after
treatment. In case of relapse, a cost was assigned to patients
including pre-treatment check-up, chemotherapy, supportive
care and follow-up. The perspective was that of the French
public health insurance. RESULTS: Patients receiving TAC had
a longer life expectancy than those treated with FAC (28.61
versus 26.33 years). Overall lifetime average costs were €20,837
and €16,143 respectively for TAC and FAC. The incremental
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cost-effectiveness ratio (ICER) was €2059 in the base case,
varying from €1474 to €4963 according to the multi-ways sen-
sitivity analysis. CONCLUSIONS: The economic assessment
shows that TAC is cost-effective in the management of early
breast cancer in France with an ICER below the threshold com-
monly cited in such analyses.
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OBJECTIVES: CALGB conducted a randomized trial to
compare the survival duration, quality of life, and costs of
hepatic artery infusion (HAI) versus systemic chemotherapy
(SYS) as initial treatment for patients with colorectal cancer
metastatic to the liver. We evaluated the lifetime incremental cost
and beneﬁt from a third-party payer perspective alongside that
trial. METHODS: Resource use data were collected for all study
patients through 18 months, regardless of disease progression,
and a subset was followed until death. Unit costs were derived
from itemized patient bills, adjusted using department-speciﬁc
ratios of costs to charges. Utility weights were collected serially
from trial patients and used to calculate quality-adjusted sur-
vival. RESULTS: During the ﬁrst 18 months, inpatient stays
accounted for the highest proportion of overall costs (47%) in
the HAI arm, while outpatient visits were the major component
of costs (40%) in the SYS arm. In both arms, non-protocol
chemotherapy treatment given after progression accounted for
approximately half of all outpatient care costs. Compared to sys-
temic 5-ﬂuorouracil and leucovorin, hepatic artery infusion of
ﬂoxuridine increased quality-adjusted survival by 0.46 quality-
adjusted life years, at an incremental cost of $50,867. Most of
the difference in costs occurred early, and was attributable to
higher inpatient care and surgery costs. The incremental cost-
effectiveness ratio (ICER) was $112,924 per quality-adjusted life
year. The bootstrap-derived distribution of ICER was quite
precise, with only 28% and 90% of simulations falling under
$100,000/QALY and $200,000/QALY, respectively. The magni-
tude of the ICER was robust in sensitivity analyses. CONCLU-
SIONS: Hepatic artery infusion for metastatic colorectal cancer
resulted in a substantial increase in quality-adjusted survival at
an ICER that compares favorably with other widely used cancer
treatments in the United States. These results create a benchmark
against which the costs and cost-effectiveness of new agents can
and should be evaluated.
PCN14
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OBJECTIVE: Anemia, a common complication of chemother-
apy, is often treated with erythropoiesis-stimulating proteins.
The objective of this study was to assess the cost-effectiveness of
once every three weeks (Q3W) 500mg Aranesp® (darbepoetin
alfa) administration compared to a weekly 150mg (QW) regimen
from a French societal perspective. METHOD: A decision-tree
model with a 16-week time horizon was developed in Excel®.
This model included the possibility to adapt darbepoetin alfa
dosing based on hemoglobin (Hb) criteria reported in guidelines.
The transition probabilities, the number of days with Hb ≥ 11
g/dL (effectiveness measure), and the units of blood transfused
were extracted from a randomized clinical trial. Unit costs were
applied to medical resources used (transfusions, darbepoetin
alfa, physician visits, hospitalizations, and administration time
by health care professionals) and patients’ time. Literature data,
validated by two French clinical experts, was used for inputs
regarding resource use. Time was valued at gross hourly wage
rate. Both time and medical costs were extracted from ofﬁcial
sources (AMELI; INSEE) and adjusted to 2005 values. A 5000-
replication probabilistic sensitivity analysis was performed with
@RISK® using distributions for both probabilities and time.
RESULTS: The effectiveness was similar between the two arms.
Switching patients from QW to Q3W resulted in a gain of 2.3
days with Hb ≥ 11g/dL (95% CI: -3.3; 7.6). Total costs were
slightly lower for Q3W (€4616 [95% CI: 4303; 4959]) compared
to QW (€4856 [95% CI: €4488; 5258]). Probabilistic sensitivity
analysis revealed 68% of replications with higher effectiveness
and lower costs for Q3W treatment (dominant); 11% with both
higher effectiveness and costs; 4% where Q3W was dominated
by QW and 17% showed both lower effectiveness and costs.
CONCLUSION: This analysis provides probabilistic informa-
tion to decision makers about the health economic impact of dar-
bepoetin alfa Q3W. A decision in favor of Q3W is more likely
to be beneﬁcial from a health economic viewpoint.
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OBJECTIVE: To estimate the cost-effectiveness of adjuvant
treatment with exemestane vs. tamoxifen for early-stage breast
cancer after 2–3 years treatment with tamoxifen, in Spain.
METHODS: A Markov state-transition model was performed
from the National Health System perspective, and simulates the
long-term outcomes over 10 and 20 years. The primary outcome
was the incremental cost-effectiveness of exemestane scheme in
terms of cost per quality-adjusted life year (QALY) gained. The
transition probabilities between health states (disease-free sur-
vival with or without complications, local recurrence, contralat-
eral breast cancer, systemic recurrence or dead) were derived
from the Intergroup Exemestane Study (IES) trial and from sec-
ondary Spanish sources. The costs associated with chemother-
apy and complications (bone fractures, vaginal bleeding, venous
thromboembolism, myocardial infarction) and unit costs
(€2005) were obtained from Spanish treatment guidelines and
Spanish health costs databases. A literature review was con-
ducted to derive the utility data. RESULTS: The average addi-
tional QALY per exemestane-treated patients were 0.200 and
0.557, for 10 and 20 years, respectively, compared with that of
tamoxifen alone scheme. The additional cost per QALY gained
obtained with exemestane was €70,990 and €39,170, respec-
tively. The sensitivity analyses conﬁrmed the robustness of the
base case analysis. CONCLUSIONS: According to this model,
adjuvant exemestane therapy after 2–3 years of tamoxifen
therapy signiﬁcantly improved disease-free survival as compared
